OncoMatch/Clinical Trials/NCT05904080
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
Is NCT05904080 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ipilimumab and Nivolumab for metastatic nasopharyngeal carcinoma.
Treatment: Cabozantinib S-malate · Ipilimumab · Nivolumab — This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy (platinum-gemcitabine) — recurrent/metastatic
disease treated with platinum-gemcitabine
Must have received: anti-PD-1/PD-L1 therapy — recurrent/metastatic
prior PD-1/L1 blockade (as first or second-line therapy) where immunotherapy was part of the most recent prior line of therapy
Cannot have received: VEGFR inhibitor
No prior VEGFR targeted therapy permitted
Lab requirements
Blood counts
ANC >= 1,000/mm^3; Hemoglobin >= 9 g/dL; Platelet count >= 100,000/mm^3
Kidney function
Creatinine or creatinine clearance <= 1.5 mg/dL or >= 30 mL/min (MDRD)
Liver function
Total bilirubin <= 1.5 x institutional upper limit of normal (ULN); except subjects with Gilbert syndrome who can have a total bilirubin < 3 mg/dL; AST/ALT <= 3 x ULN (up to <= 5 x ULN with liver metastases)
ANC >= 1,000/mm^3; Hemoglobin >= 9 g/dL; Platelet count >= 100,000/mm^3; Creatinine or creatinine clearance <= 1.5 mg/dL or >= 30 MDRD; Total bilirubin <= 1.5 x institutional ULN; except subjects with Gilbert syndrome who can have a total bilirubin < 3 mg/dL; AST/ALT <= 3 x ULN (up to <= 5 x ULN with liver metastases)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, California
- Keck Medicine of USC Koreatown · Los Angeles, California
- Los Angeles General Medical Center · Los Angeles, California
- USC / Norris Comprehensive Cancer Center · Los Angeles, California
- USC Norris Oncology/Hematology-Newport Beach · Newport Beach, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify